EP3672571
LYFJAFRÆÐILEG VATNSBLANDA SEM INNIHELDUR 1-(4-{[4-DÍMETÝLAMÍNÓ)PÍPERIDÍN-1-ÝL]KARBONÝL}FENÝL)-3-[4-(4,6-DÍMORFÓLÍN-4-ÝL-1,3,5-TRÍASÍN-2-ÝL)FENÝL]ÞVAGEFNI
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
20.8.2018EP published:
6.10.2021EP application number:
18769793.3
EP translation filed:
3.11.2021Grant published:
15.1.2022EPO information:
European Patent Register
Max expiry date:
19.8.2038Expiry date:
19.8.2026Next due date:
31.8.2026
Title:
PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA
Timeline
Today
20.8.2018EP application
6.10.2021EP Publication
3.11.2021Translation submitted
15.1.2022Registration published
19.8.2026Expires
Owner
Name:
Pfizer Inc.Address:
235 East 42nd Street, New York, NY 10017, US
Inventor
Name:
HUSSEY, James JosephAddress:
Sandwich Kent CT13 9NJ, GB
Name:
BRIGHT, Andrew GilbertAddress:
Sandwich Kent CT13 9NJ, GB
Agent
Name:
Tego IP ehf.Address:
Pósthólf 8129, 128, Reykjavík,
Priority
Number:
201762550007 PDate:
25.8.2017Country:
US
Number:
201862681720 PDate:
7.6.2018Country:
US
Number:
201862703022 PDate:
25.7.2018Country:
US
Classification
Categories:
A61K 9/00, A61K 9/19, A61K 47/20, A61K 47/40, A61P 35/00, A61P 35/02, A61K 31/5377
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 2.8.2022
Expires: 19.8.2023
Payer: Patice ehf.
Number: 6
Paid: 28.8.2023
Expires: 19.8.2024
Payer: Árnason Faktor ehf.
Number: 7
Paid: 22.8.2024
Expires: 19.8.2025
Payer: Árnason Faktor ehf.
Number: 8
Paid: 13.8.2025
Expires: 19.8.2026
Payer: Árnason Faktor ehf.